Literature DB >> 20130408

Bioavailability of buprenorphine from crushed and whole buprenorphine (subutex) tablets.

Kaarlo Simojoki1, Pirjo Lillsunde, Nicholas Lintzeris, Hannu Alho.   

Abstract

BACKGROUND: Buprenorphine (Subutex) is the most abused opioid in Finland. In order to curb the abuse potential of this drug, many treatment centers and prisons crush Subutex tablets before administering them to patients. To date, there are no published studies comparing the efficacy and bioavailability of crushed and whole Subutex tablets.
METHODS: A total of 16 opioid-dependent patients stabilized on 24 mg of buprenorphine were enrolled in a double-blind, double-dummy, randomized cross-over study comparing crushed and whole buprenorphine tablets on a range of pharmacokinetic and pharmacodynamic variables. Buprenorphine tablets (either crushed or whole) and placebo tablets (either crushed or whole) were administered to subjects simultaneously. Buprenorphine and norbuprenorphine serum levels were measured at 30, 60, 90, 120, 180, 240 and 360 min, as well as 24 h, after tablet administration. After 1 week, the experiment was repeated in a cross-over design so that, by the end of the study, each patient had received the active drug (buprenorphine) as both crushed and whole tablets.
RESULTS: Pharmacokinetic parameters (mean serum levels, C(max), T(max), AUC) of buprenorphine or norbuprenorphine did not differ significantly between crushed and whole tablets, although serum levels were slightly higher after administration of the crushed tablets. There were also no significant differences in dissolution/absorption time, withdrawal signs or opiate craving.
CONCLUSION: We conclude that crushing Subutex tablets does not significantly alter serum buprenorphine or norbuprenorphine levels or the drug's clinical effect. Our results indicate that crushing Subutex tablets may be used as an alternative method to counter the risk of buprenorphine diversion. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130408     DOI: 10.1159/000279766

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  3 in total

1.  Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.

Authors:  Jaime R Bastian; Huijun Chen; Hongfei Zhang; Scott Rothenberger; Ralph Tarter; Dennis English; Raman Venkataramanan; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2016-09-26       Impact factor: 8.661

Review 2.  New developments in managing opioid addiction: impact of a subdermal buprenorphine implant.

Authors:  MariaLisa Itzoe; Michael Guarnieri
Journal:  Drug Des Devel Ther       Date:  2017-05-10       Impact factor: 4.162

3.  A Decision Support Tool Facilitating Medicine Design for Optimal Acceptability in The Older Population.

Authors:  Thibault Vallet; Emilie Belissa; Sandra Laribe-Caget; Alain Chevallier; François-Xavier Chedhomme; Patrick Leglise; Matthieu Piccoli; Hugues Michelon; Vanessa Bloch; Sylvie Meaume; Anne-Sophie Grancher; Nathalie Bachalat; Imad Boulaich; Fattima Abdallah; Maite Rabus; Jean-Paul Rwabihama; Annie-Claude Ribemont; Celia Lachuer; Ines Perquy; Laurent Lechowski; Anne Delahaye; Mathieu Depoisson; Yann Orven; Caroline Guinot; Stephane Gibaud; Corinne Michel; Abdel Mahiou; Sid-Ahmed Belbachir; Jean-Hugues Trouvin; Amelie Dufaÿ-Wojcicki; Vincent Boudy; Fabrice Ruiz
Journal:  Pharm Res       Date:  2018-05-07       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.